Breaking News Instant updates and real-time market news.

REGN

Regeneron

$402.02

-4.34 (-1.07%)

, SNY

Sanofi

$38.19

0.36 (0.95%)

15:09
10/02/16
10/02
15:09
10/02/16
15:09

Regeneron, Sanofi report data on Phase 3 studies of dermatitis drug Dupixent

Regeneron (REGN) and Sanofi (SNY) announced that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent, or dupilumab, in adult patients with inadequately controlled moderate-to-severe atopic dermatitis, were published in the New England Journal of Medicine. The studies met their primary endpoints evaluating the extent and severity of the disease. In addition, both trials met key secondary endpoints measuring reduction in itch, improvement in patient-reported anxiety and depression symptoms, and certain quality of life measures. Specifically, at 16 weeks for SOLO 1 and SOLO 2, respectively, 37 and 36 percent of adult patients who received Dupixent 300 mg weekly, and 38 and 36 percent of patients who received Dupixent 300 mg every two weeks, achieved clearing or near-clearing of skin lesions as measured by the 5-point Investigator's Global Assessment scale, compared to 10 and 8 percent with placebo. This was the primary endpoint of the study in the U.S. and one of the primary endpoints in the EU. At 16 weeks for SOLO 1 and SOLO 2, respectively, 52 and 48 percent of adult patients who received Dupixent 300 mg weekly, and 51 and 44 percent of patients who received Dupixent 300 mg every two weeks, achieved a 75 percent or greater reduction in their Eczema Area and Severity Index score compared to 15 and 12 percent with placebo. This was the key secondary endpoint in the U.S. and one of the primary endpoints in the EU. At 16 weeks for SOLO 1 and SOLO 2, respectively, the percent improvement in EASI from baseline was 72 and 69 percent in patients who received the 300 mg weekly dose, and 72 and 67 percent for patients who received Dupixent 300 mg every two weeks, compared to 38 and 31 percent for placebo. The reduction in the daily intensity of patient-reported itch, as measured by the Pruritus Numerical Rating Scale, was a secondary endpoint that was met at 2 weeks, 4 weeks and 16 weeks. At 16 weeks, for SOLO 1 and SOLO 2, respectively, 40 and 39 percent of patients who received Dupixent 300 mg weekly and 41 and 36 percent of patients who received Dupixent 300 mg every two weeks achieved a four-point or greater reduction in their NRS score compared to 12 and 10 percent with placebo. For the 16-week treatment period, the overall rate of adverse events -- 65-73 percent Dupixent and 65-72 percent placebo -- was comparable between the groups. The rate of serious adverse events was 1-3 percent for Dupixent and 5-6 percent for placebo. Adverse events that were noted to have a higher rate with Dupixent treatment across both studies included injection site reactions -- 8-19 percent Dupixent; 6 percent placebo -- and conjunctivitis. No patients discontinued therapy due to injection site reactions and one patient discontinued therapy due to conjunctivitis.

REGN

Regeneron

$402.02

-4.34 (-1.07%)

SNY

Sanofi

$38.19

0.36 (0.95%)

  • 07

    Oct

  • 30

    Oct

  • 29

    Mar

REGN Regeneron
$402.02

-4.34 (-1.07%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
08/05/16
BARD
08/05/16
DOWNGRADE
Target $448
BARD
Neutral
Regeneron downgraded to Neutral at Baird
As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.
08/05/16
LEER
08/05/16
NO CHANGE
Target $511
LEER
Outperform
Regeneron price target lowered to $511 from $530 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron to $511 from $530, citing cautious guidance following the company's Q2 results. Nonetheless, the analyst points out its Eylea "solid" sales, beating by 2% in the U.S. and 5% overall. The analyst remains positive about Regeneron's product portfolio, strategy, management, and long-term potential. He reiterates an Outperform rating on the shares.
SNY Sanofi
$38.19

0.36 (0.95%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Sanofi initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Sanofi with a Neutral rating and EUR 76 price target.
09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Neutral
Sanofi upgraded to Neutral from Underperform at Exane BNP Paribas
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/08/16
09/08/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Overweight from Neutral at JPMorgan with analyst Chris Schott saying new products could drive upside to 2017 estimates while the risk/reward is favorable into solanezumab data late this year. 2. Johnson Controls (JCI) upgraded to Outperform from Neutral at Macquarie with analyst Mike Wood saying he has increased confidence on the commercial recovery, upside to Tyco synergies, improving cash flow, and potential for further portfolio simplification. 3. Sanofi (SNY) upgraded to Buy from Hold at Berenberg. 4. VMware (VMW) reinstated with Overweight from Neutral at JPMorgan with analyst Mark Murphy saying partner interviews highlight strength in the company's products and Dell has publicly stated that its global distribution network can lead to $1B of incremental VMware revenue. 5. Volaris (VLRS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.